retatrutide phase 3 triumph 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Trial New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most ⭐️topline results from TRIUMPH-1, a

The TRIUMPH-4 Phase 3 trial in obesity with knee osteoarthritis (Bays et al., NEJM 2025) reported 28.7% mean weight loss at 68 weeks at the 12 mg dose, plus a 75.8% reduction in WOMAC knee pain scores

These medications initially were approved as a treatment for diabetes and work by mimicking the GLP-1 hormone, which is secreted from the intestine

This formula also includes Fucoxanthin, a plant-based antioxidant found in certain green superfoods

Tirzepatide produces approximately 20-22% body weight reduction at its highest approved dose of 15mg weekly, which is closer to retatrutide performance than semaglutide is

Standard prescription access requires FDA approval, projected for late 2027 to 2028

If nausea persists, dosing can be reviewed